GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Cash Flow from Operations

BIOA (Bioage Labs) Cash Flow from Operations : $-51.52 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2024, Bioage Labs's Net Income From Continuing Operations was $-21.13 Mil. Its Depreciation, Depletion and Amortization was $0.05 Mil. Its Change In Working Capital was $13.58 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $2.72 Mil. And its Cash Flow from Others was $-0.36 Mil. In all, Bioage Labs's Cash Flow from Operations for the three months ended in Dec. 2024 was $-5.14 Mil.


Bioage Labs Cash Flow from Operations Historical Data

The historical data trend for Bioage Labs's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Cash Flow from Operations Chart

Bioage Labs Annual Data
Trend Dec22 Dec23 Dec24
Cash Flow from Operations
-36.18 -37.36 -51.52

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only -8.50 -15.67 -15.78 -14.93 -5.14

Bioage Labs Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Bioage Labs's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

Bioage Labs's Cash Flow from Operations for the quarter that ended in Dec. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioage Labs  (NAS:BIOA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Bioage Labs's net income from continuing operations for the three months ended in Dec. 2024 was $-21.13 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Bioage Labs's depreciation, depletion and amortization for the three months ended in Dec. 2024 was $0.05 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Bioage Labs's change in working capital for the three months ended in Dec. 2024 was $13.58 Mil. It means Bioage Labs's working capital increased by $13.58 Mil from Sep. 2024 to Dec. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Bioage Labs's cash flow from deferred tax for the three months ended in Dec. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Bioage Labs's cash from discontinued operating Activities for the three months ended in Dec. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Bioage Labs's asset impairment charge for the three months ended in Dec. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Bioage Labs's stock based compensation for the three months ended in Dec. 2024 was $2.72 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Bioage Labs's cash flow from others for the three months ended in Dec. 2024 was $-0.36 Mil.


Bioage Labs Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioage Labs Business Description

Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Bioage Labs Headlines

From GuruFocus